{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:51:31Z","timestamp":1774003891347,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"the Susan G Komen Foundation"},{"DOI":"10.13039\/100000054","name":"US National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Rossy Family Foundation"},{"DOI":"10.13039\/501100004099","name":"La Ligue Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Cancer League"},{"name":"Swiss Cancer Research foundation"},{"DOI":"10.13039\/501100006505","name":"Swiss Re","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Ministry of Health, Labor and Welfare","award":["23EA1033"],"award-info":[{"award-number":["23EA1033"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain tumors are a serious health issue, and survival is an effective indicator of how the healthcare system manages them. We examined net survival trends for patients diagnosed with a primary brain tumor during 2000\u20132014 in Japan, using data from 16 regional population-based cancer registries participating in the CONCORD-3 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients aged 15\u201399\u00a0years, with follow-up completed either 5\u00a0years after diagnosis or up to 31 December, 2014. We estimated 5-year net survival by age group and morphological subtype using the Pohar Perme estimator, and age-standardized with International Cancer Survival Standard weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five-year net survival for brain tumors increased from 27.9% for patients diagnosed during 2000\u20132004 to 46.3% in 2010\u20132014. During 2010\u20132014, 5-year net survival for astrocytic tumors was 22.3%, but ~90% for neuronal and mixed neuro-glial tumors, germ cell tumors, and other specified tumors. Five-year net survival reached 62.1% for oligodendroglial and oligoastrocytic tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Five-year net survival for brain tumors in Japan improved during 2000\u20132014, with remarkable variations by morphologic type. Survival improved for all age groups, and particularly for younger patients, highlighting the need for enhanced survivorship care. Japan\u2019s focus on comprehensive data collection and supportive care for longer-term survivors remains key for further progress. When compared<\/jats:p>\n                    <jats:p>internationally, Japan\u2019s gains sit at the higher end of reported survival ranges, underscoring how robust registry infrastructure and equitable access to care could inform strategies for brain tumor care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf165","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:18:38Z","timestamp":1760012318000},"page":"i94-i102","source":"Crossref","is-referenced-by-count":0,"title":["Trends in net survival for patients with brain tumors in Japan, 2000\u201314 (CONCORD-3)"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3235","authenticated-orcid":false,"given":"Laureline","family":"Gatellier","sequence":"first","affiliation":[{"name":"Division of International Health Policy Research, Institute for Cancer Control, National Cancer Center. 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Matz","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine. Keppel Street , London WC1E 7HT,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-0865","authenticated-orcid":false,"given":"Hiromi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Radiation Effects Research Foundation. 5-2 Hijiyama Park, Minami-ku , Hiroshima 732-0815 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5200-9310","authenticated-orcid":false,"given":"Izumi","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Saitama Prefectural University. 820 Sannomiya, Koshigaya-shi , Saitama 343-8540 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Yamagata Prefectural Central Hospital. 1800 Oaza-Aoyanagi, Yamagata City , Yamagata 990-2214 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-8637","authenticated-orcid":false,"given":"Kayo","family":"Nakata","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute. 3-1-69 Otemae, Chuo-ku, Osaka city 541-8567, Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari Kajiwara","family":"Saito","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute. 3-1-69 Otemae, Chuo-ku, Osaka city 541-8567, Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-3037","authenticated-orcid":false,"given":"Masashi","family":"Matsuzaka","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Hirosaki University Hospital. 53, Honcho, Hirosaki , Aomori 036-8563 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1147","authenticated-orcid":false,"given":"Isao","family":"Oze","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control, Aichi Cancer Center Research Institute. 1-1 Kanokoden, Chikusa-ku, Nagoya , Aichi 464-8681 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-5283","authenticated-orcid":false,"given":"Kaname","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Division, Kanagawa Cancer Center Research Institute. 2-3-2 Nakao, Asahi-ku , Yokohama, Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-0644","authenticated-orcid":false,"given":"Rina","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Hirosaki University Graduate School of Medicine. 5, zaifucho, Hirosaki , Aomori 036-8562 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-2505","authenticated-orcid":false,"given":"Marisa","family":"Nishio","sequence":"additional","affiliation":[{"name":"Division of Prevention, Institute for Cancer Control, National Cancer Center. 5-1-1 Tsukiji, Chuo-ku , Tokyo 104-0045 ,","place":["Japan"]},{"name":"Department of Medical Statistics , Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-0507","authenticated-orcid":false,"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology, NHO Shikoku Cancer Center. Minamiumenomoto-cho, Matsuyama , Ehime 791-0280 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-4581","authenticated-orcid":false,"given":"Hidemi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control, Aichi Cancer Center Research Institute. 1-1 Kanokoden, Chikusa-ku, Nagoya , Aichi 464-8681 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-1871","authenticated-orcid":false,"given":"Norihiro","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Epidemiology, Center for Cancer Research, Shikoku Cancer Center. Minamiumenomoto-cho, Matsuyama , Ehime 791-0280 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Epidemiology, Center for Cancer Research, Shikoku Cancer Center. Minamiumenomoto-cho, Matsuyama , Ehime 791-0280 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Kaizaki","sequence":"additional","affiliation":[{"name":"Fukui Prefectural Hospital. 2-8-1 Yotsui, Fukui-city , Fukui 910-8526 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Moki","sequence":"additional","affiliation":[{"name":"Gunma Health Foundation . 16-1 Horinoshita-machi, Maebashi, Gunma 371-0005 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuki","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Ibaraki Prefectural Office. 978-6, Kasahara-cho, Mito , Ibaraki 310-8555 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Ibaraki Pharmaceutical Association Inspection Center. 978-47, Kasahara-cho, Mito , Ibaraki 310-0852 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-4911","authenticated-orcid":false,"given":"Hiroto","family":"Narimatsu","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Division, Kanagawa Cancer Center Research Institute. 2-3-2 Nakao, Asahi-ku , Yokohama, Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiki","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Miyagi Cancer Center Research Institute. 47-1 Nodayama, Medeshima-Shiote, Natori , Miyagi 981-1293 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Miyashiro","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute. 3-1-69 Otemae, Chuo-ku, Osaka city 541-8567, Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Mori","sequence":"additional","affiliation":[{"name":"Saga-ken Medical Centre Koseikan. 400 Nakabaru, Kasemachi , Saga 840-8571 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujita","sequence":"additional","affiliation":[{"name":"Tochigi Cancer Center. 4-9-13, Yohnan , Utsunomiya, Tochigi 320-0834 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-1233","authenticated-orcid":false,"given":"Tomohiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Division of International Health Policy Research, Institute for Cancer Control, National Cancer Center. 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-532X","authenticated-orcid":false,"given":"Michel P","family":"Coleman","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine. Keppel Street , London WC1E 7HT,","place":["United Kingdom"]},{"name":"Cancer Division , University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-3766","authenticated-orcid":false,"given":"Claudia","family":"Allemani","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine. Keppel Street , London WC1E 7HT,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-9526","authenticated-orcid":false,"given":"Veronica","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine. Keppel Street , London WC1E 7HT,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026032004354624300_ref1","doi-asserted-by":"publisher","first-page":"e000666","DOI":"10.1136\/esmoopen-2019-000666","article-title":"Rationale of the rare cancer list: a consensus paper from the joint action on rare cancers (JARC) of the European Union (EU)","volume":"5","author":"Casali","year":"2020","journal-title":"ESMO Open"},{"key":"2026032004354624300_ref2","volume-title":"Cancer Today - Population fact sheet: Global Cancer Observatory","author":"International Agency for Research on Cancer","year":"(): ; 2022"},{"key":"2026032004354624300_ref3","volume-title":"2016 WHO classification of tumours of the central nervous system","author":"Louis","year":"2016"},{"key":"2026032004354624300_ref4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet."},{"key":"2026032004354624300_ref5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/neuonc\/noac217","article-title":"Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3)","volume":"25","author":"Girardi","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026032004354624300_ref6"},{"key":"2026032004354624300_ref7","first-page":"140","article-title":"ICD-O-3 terminology approved for use with cases diagnosed January 1, 2014 and after","volume":"40","author":"Fritz","year":"2013","journal-title":"J Registry Manag"},{"key":"2026032004354624300_ref8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Pohar Perme","year":"2012","journal-title":"Biometrics."},{"key":"2026032004354624300_ref9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9&lt;2004::AID-CNCR23&gt;3.0.CO;2-#","article-title":"An alternative approach to monitoring cancer patient survival","volume":"78","author":"Brenner","year":"1996","journal-title":"Cancer."},{"key":"2026032004354624300_ref10"},{"key":"2026032004354624300_ref11"},{"key":"2026032004354624300_ref12"},{"key":"2026032004354624300_ref13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1186\/s12889-015-2534-3","article-title":"Multivariable flexible modelling for estimating complete, smoothed life tables for sub-national populations","volume":"15","author":"Rachet","year":"2015","journal-title":"BMC Public Health"},{"key":"2026032004354624300_ref14","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","article-title":"Standard cancer patient population for age standardising survival ratios","volume":"40","author":"Corazziari","year":"2004","journal-title":"Eur J Cancer"},{"key":"2026032004354624300_ref15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1536867X1401400107","article-title":"Net survival estimation with Stns","volume":"14","author":"Clerc-Urm\u00e8s","year":"2014","journal-title":"Stata J"},{"key":"2026032004354624300_ref16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2176\/nmc.oa.2016-0172","article-title":"Current trends and healthcare resource usage in the hospital treatment of primary malignant brain tumor in Japan: a National Survey Using the diagnostic procedure combination database (J-ASPECT study-brain tumor)","volume":"56","author":"Yoshimoto","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2026032004354624300_ref17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026032004354624300_ref18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14551"},{"key":"2026032004354624300_ref19","volume-title":"Glioma treatment guidelines: Japanese Society for Neuro-Oncology","author":"Japan Society for Neuro-Oncology","year":"2024"},{"key":"2026032004354624300_ref20","volume-title":"Glioblastoma treatment guideline: Japan Society for Neuro-Oncology.","author":"Japan Society for Neuro-Oncology","year":"2024","edition":"3rd"},{"key":"2026032004354624300_ref21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026032004354624300_ref22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1586\/ern.12.66","article-title":"Molecular subgroups of medulloblastoma","volume":"12","author":"Northcott","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"2026032004354624300_ref23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrneurol.2012.78","article-title":"The clinical implications of medulloblastoma subgroups","volume":"8","author":"Northcott","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"2026032004354624300_ref24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bpa.12837","article-title":"Pathology, diagnostic, and classification of medulloblastoma","volume":"30","author":"Brent","year":"2020","journal-title":"Brain Pathol"},{"key":"2026032004354624300_ref25","first-page":"211","article-title":"Primary brain tumors in adults: diagnosis and treatment","volume":"93","author":"Perkins","year":"2016","journal-title":"Am Fam Physician"},{"key":"2026032004354624300_ref26","doi-asserted-by":"publisher","DOI":"10.15761\/ICST.1000255","article-title":"Prognosis of older patients with low-grade glioma: a retrospective study","volume":"4","author":"Kumthekar","year":"2017","journal-title":"Integr Cancer Sci Ther"},{"key":"2026032004354624300_ref27","doi-asserted-by":"publisher","author":"Fjell","DOI":"10.1017\/9781108552684.004"},{"key":"2026032004354624300_ref28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00520-021-06567-1","article-title":"Impact of comorbidities on physical function and survival of middle-aged, as compared to older, individuals with cancer","volume":"30","author":"Koczwara","year":"2022","journal-title":"Support Care Cancer"},{"key":"2026032004354624300_ref29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/CCO.0000000000001078","article-title":"Patient-reported outcomes in neuro-oncology","volume":"36","author":"Scheepens","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"2026032004354624300_ref30","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae084","article-title":"Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: a feasibility study","volume":"6","author":"Darlix","journal-title":"Neurooncol Adv"},{"key":"2026032004354624300_ref31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"Koekkoek","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026032004354624300_ref32"},{"key":"2026032004354624300_ref33"},{"key":"2026032004354624300_ref34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jjco\/hyv023","article-title":"Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan","volume":"45","author":"Saika","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2026032004354624300_ref35"},{"key":"2026032004354624300_ref36","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.ejca.2015.07.032","article-title":"Survival of adults with primary malignant brain tumours in Europe; results of the EUROCARE-5 study","volume":"51","author":"Visser","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/Supplement_1\/i94\/67423394\/hyaf165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/Supplement_1\/i94\/67423394\/hyaf165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:35:58Z","timestamp":1773995758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/Supplement_1\/i94\/8529742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf165","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}